AUPH vs. NBIX
AUPH (Aurinia Pharmaceuticals Inc.) and NBIX (Neurocrine Biosciences, Inc.) are both stocks. Both are in the Healthcare sector — AUPH in Biotechnology, NBIX in Drug Manufacturers - Specialty & Generic. Over the past 10 years, AUPH returned 18.49%/yr vs 13.16%/yr for NBIX. At a 0.25 correlation, their price movements are largely independent.
Performance
AUPH vs. NBIX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, AUPH achieves a -0.82% return, which is significantly lower than NBIX's 12.64% return. Over the past 10 years, AUPH has outperformed NBIX with an annualized return of 18.49%, while NBIX has yielded a comparatively lower 13.16% annualized return.
AUPH
- 1D
- -0.19%
- 1M
- -1.31%
- YTD
- -0.82%
- 6M
- -0.19%
- 1Y
- 92.22%
- 3Y*
- 16.72%
- 5Y*
- 4.23%
- 10Y*
- 18.49%
NBIX
- 1D
- -1.81%
- 1M
- -0.97%
- YTD
- 12.64%
- 6M
- 4.55%
- 1Y
- 27.80%
- 3Y*
- 18.64%
- 5Y*
- 10.13%
- 10Y*
- 13.16%
AUPH vs. NBIX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
AUPH Aurinia Pharmaceuticals Inc. | -0.82% | 77.62% | -0.11% | 108.10% | -81.11% | 65.37% | -31.74% | 197.07% | 50.55% | 115.71% |
NBIX Neurocrine Biosciences, Inc. | 12.64% | 3.90% | 3.60% | 10.31% | 40.24% | -11.14% | -10.83% | 50.53% | -7.96% | 100.49% |
Correlation
The correlation between AUPH and NBIX is 0.29, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.29 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.27 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.27 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.27 |
Correlation (All Time) Calculated using the full available price history since Sep 3, 2014 | 0.25 |
Fundamentals
AUPH:
$2.18B
NBIX:
$16.52B
AUPH:
$2.15
NBIX:
$6.53
AUPH:
7.37
NBIX:
24.46
AUPH:
0.00
NBIX:
0.48
AUPH:
7.37
NBIX:
5.27
AUPH:
3.84
NBIX:
4.85
AUPH:
$298.30M
NBIX:
$3.10B
AUPH:
$267.70M
NBIX:
$3.05B
AUPH:
$153.45M
NBIX:
$881.20M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
AUPH vs. NBIX — Risk / Return Rank
AUPH
NBIX
AUPH vs. NBIX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Aurinia Pharmaceuticals Inc. (AUPH) and Neurocrine Biosciences, Inc. (NBIX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| AUPH | NBIX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.15 | ||
| Sortino ratioReturn per unit of downside risk | +1.26 | ||
| Omega ratioGain probability vs. loss probability | 1.38 | 1.19 | +0.19 |
| Calmar ratioReturn relative to maximum drawdown | 5.83 | 1.34 | +4.49 |
| Martin ratioReturn relative to average drawdown | 12.68 | 2.94 | +9.75 |
Loading charts...
Drawdowns
AUPH vs. NBIX - Drawdown Comparison
The maximum AUPH drawdown since its inception was -87.58%, smaller than the maximum NBIX drawdown of -97.21%. Use the drawdown chart below to compare losses from any high point for AUPH and NBIX.
Loading charts...
Drawdown Indicators
| AUPH | NBIX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -87.58% | -97.21% | +9.63% |
Max Drawdown (1Y)Largest decline over 1 year | -15.91% | -20.90% | +4.99% |
Max Drawdown (3Y)Largest decline over 3 years | -60.80% | -42.89% | -17.91% |
Max Drawdown (5Y)Largest decline over 5 years | -87.58% | -42.89% | -44.69% |
Max Drawdown (10Y)Largest decline over 10 years | -87.58% | -46.39% | -41.19% |
Current DrawdownCurrent decline from peak | -52.18% | -4.54% | -47.64% |
Average DrawdownAverage peak-to-trough decline | -49.21% | -43.84% | -5.37% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.30% | 9.49% | -2.19% |
Volatility
AUPH vs. NBIX - Volatility Comparison
The current volatility for Aurinia Pharmaceuticals Inc. (AUPH) is 9.07%, while Neurocrine Biosciences, Inc. (NBIX) has a volatility of 9.63%. This indicates that AUPH experiences smaller price fluctuations and is considered to be less risky than NBIX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| AUPH | NBIX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.07% | 9.63% | -0.56% |
Volatility (6M)Calculated over the trailing 6-month period | 23.92% | 23.91% | +0.01% |
Volatility (1Y)Calculated over the trailing 1-year period | 45.50% | 31.38% | +14.12% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 67.46% | 32.73% | +34.73% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 73.95% | 39.13% | +34.82% |
Dividends
AUPH vs. NBIX - Dividend Comparison
Neither AUPH nor NBIX has paid dividends to shareholders.
Financials
AUPH vs. NBIX - Financials Comparison
This section allows you to compare key financial metrics between Aurinia Pharmaceuticals Inc. and Neurocrine Biosciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
AUPH vs. NBIX - Profitability Comparison
AUPH - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Aurinia Pharmaceuticals Inc. reported a gross profit of 71.20M and revenue of 77.71M. Therefore, the gross margin over that period was 91.6%.
NBIX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported a gross profit of 800.70M and revenue of 814.50M. Therefore, the gross margin over that period was 98.3%.
AUPH - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Aurinia Pharmaceuticals Inc. reported an operating income of 41.42M and revenue of 77.71M, resulting in an operating margin of 53.3%.
NBIX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported an operating income of 193.40M and revenue of 814.50M, resulting in an operating margin of 23.7%.
AUPH - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Aurinia Pharmaceuticals Inc. reported a net income of 34.36M and revenue of 77.71M, resulting in a net margin of 44.2%.
NBIX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported a net income of 197.90M and revenue of 814.50M, resulting in a net margin of 24.3%.
Frequently Asked Questions
AUPH and NBIX have a correlation of 0.29, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NBIX has higher volatility (9.63%) compared to AUPH (9.07%). In terms of maximum drawdown, AUPH dropped -87.58% vs NBIX's -97.21%.
AUPH currently has the higher Sharpe Ratio (2.04 vs 0.89), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for AUPH and NBIX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer